GRCE Stock Summary and Trading Ideas (Grace Therapeutics | NASDAQ:GRCE)

Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.

Grace Therapeutics trades on the NASDAQ stock market under the symbol GRCE.

As of September 18, 2026, GRCE stock price declined to $2.11 with 80,494 million shares trading.

GRCE has a beta of 0.15, meaning it tends to be less sensitive to market movements. GRCE has a correlation of 0.00 to the broad based SPY ETF.

GRCE has a market cap of $44.39 million. This is considered a Sub-Micro Cap stock.

Last quarter Grace Therapeutics reported $0 in Revenue and -$.91 earnings per share. This fell short of revenue expectation by $-545,000 and missed earnings estimates by -$.73.

The top ETF exchange traded funds that GRCE belongs to (by Net Assets): VTI, IWC.

GRCE has underperformed the market in the last year with a return of -32.4%, while the SPY ETF gained +16.8%. In the last 3 month period, GRCE fell short of the market, returning -11.3%, while SPY returned +2.3%. However, in the most recent 2 weeks GRCE has outperformed the stock market by returning +0.5%, while SPY returned -0.9%.

GRCE support price is $2.05 and resistance is $2.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRCE shares will trade within this expected range on the day.